Business Wire

Alentis Therapeutics Raises USD 67 Million in Series B Financing

Share

Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round. The funding will be used primarily for proof-of-concept clinical trials of Alentis’ first in class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.

Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital.

"Our investors recognize the high unmet medical need,” said Dr. Roberto Iacone, CEO of Alentis, “They feel a great sense of urgency to develop innovative treatments for patients with life-threatening fibrotic diseases as well as related deadly cancers such as hepatocellular carcinoma and cholangiocarcinoma.” Dr. Iacone added, “This will fuel our strategy of expanding the indications for Claudin-1 targeting agents and further build our pipeline of proprietary product candidates.

Prof. Thomas Baumert, founder of Alentis, said that in the US and Europe alone, about 45% of deaths can be attributed to fibrotic disorders. He said that fibrosis affects nearly all tissues and organ systems such as the liver, kidneys and lungs.

“Fibrosis is an important risk factor for cancer, and Claudin-1 has a well-established role in cancer biology including tumor invasion and metastasis,” Prof. Baumert said. “Given the absent and unsatisfactory treatment options, it’s critical that we deliver new therapeutics for patients suffering from fibrosis and cancer.”

In addition, Alentis welcomed Jason Dinges of Morningside and Rafaèle Tordjman, founder and CEO of Jeito Capital, to its Board of Directors, effective immediately.

“We are excited about Alentis’ first-in-class approach to potentially enable effective treatments for fibrotic diseases with significant unmet medical need,” said Dr. Dinges. “We look forward to supporting this exceptional team as they pioneer modulation of Claudin-1, an important and highly promising target in fibrosis and oncology.”

“Our investment in Alentis is very much in line with Jeito’s goal to accelerate the growth of companies developing treatments for severely ill patients with no other options. We provide input into the science right through to the product’s market access,” said Dr. Tordjman. “Alentis has an outstanding and experienced team from pharma and biotech and is focused on a unique target, based on the founder’s work and his team of more than 10 years.”

Alentis' unique therapeutic approach focuses on the inhibition of Claudin-1 outside the tight junction and its downstream signalling acting on cell fate and plasticity. Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer. In preclinical studies, the lead molecule ALE.F02 modulates the function of non-junctional Claudin-1, preventing, and possibly reversing, the growth of fibrotic tissue within the liver and kidney by changing the plasticity of key cell types mediating fibrosis. Safety studies in non-human primates have supported translatability of the approach into patients. Alentis expects to initiate its first clinical trial in Q4 2021.

About Alentis Therapeutics

Alentis Therapeutics is a Swiss-based biotech that focuses on developing breakthrough treatments for fibrotic diseases. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

The Company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need. Furthermore, the company uses a patient-derived drug and target discovery platform to develop medicines for advanced fibrosis.

Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.

For more information, visit https://alentis.ch/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nathalie Graf-Tschupp
Office Manager
nathalie.graf@alentis.ch

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bentley Systems Announces Seequent’s Acquisition of Imago3.8.2021 23:14:00 EEST | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Seequent business unit has acquired Imago Inc, a developer of cloud-based software for the capture and management of geoscientific imagery. The acquisition will expand Seequent’s technology solutions portfolio while boosting cloud capabilities to help geoscientists and engineers solve earth, environment, and energy challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210803006032/en/ Imago establishes a consistent process for capturing high-quality images, which integrate with existing workflows and allow the application of machine learning. Imago instantly displays machine learning insights together with images during interpretation and modeling. Imago’s on-screen masking and classification tools export data to train models. The Imago Cloud library of geology images provides rich information that supp

Riskified Ltd. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares3.8.2021 23:10:00 EEST | Press release

Riskified Ltd. (“Riskified”), a fraud management platform enabling frictionless eCommerce, announced the closing of its initial public offering of 20,125,000 Class A ordinary shares on August 2, 2021, including the exercise in full by the underwriters of their option to purchase 2,625,000 additional shares of Class A ordinary shares, at a price of $21.00 per Class A ordinary share. The offering consisted of 19,925,000 Class A ordinary shares offered by Riskified and 200,000 Class A ordinary shares to be sold by one of Riskified’s existing shareholders. Riskified will not receive any proceeds from the sale of the shares by the selling shareholder. The gross proceeds to Riskified, before deducting underwriting discounts and commissions and offering expenses, were approximately $418 million. The Class A ordinary shares began trading on the New York Stock Exchange on July 29, 2021 under the ticker symbol “RSKD”. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse Securiti

Andersen Global Expands into Puerto Rico with San Juan-Based Law Firm3.8.2021 16:30:00 EEST | Press release

Andersen Global extends its reach into the Puerto Rican market with San Juan-based law firm Casillas, Santiago & Torres, LLC (CST Law). Founded in 2011, CST Law is a full-service firm focusing on business and commercial law with capabilities in corporate, tax, commercial and employment law litigation, real estate, immigration, labor and employment law, employee benefits and government affairs. The firm covers a variety of industries such as retail, wholesale, real estate, manufacturing, tourism, financial services, technology, telecommunications and construction, providing legal services to a range of clients including major multinational companies. “Our firm has built long-lasting relationships with our clients through our commitment to transparency and quality of work we provide,” said Managing Partner Luis L. Torres. “As our clients’ operations continue to expand into multiple jurisdictions, their need for integrated and seamless services also increases. Our collaboration with Ander

IDEMIA Top Leader in NIST Flight Boarding Simulation Showcasing High Accuracy of Algorithms3.8.2021 16:30:00 EEST | Press release

IDEMIA, the global leader in augmented identity, announced today that the company ranked second for passenger identification in the latest testing by the National Institute of Standards (NIST), confirming that IDEMIA’s facial recognition technology and algorithms are among the most accurate, fair and consistent in market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210803005333/en/ Credits : IDEMIA The test focuses on ‘Identification for Paperless Travel and Immigration’ and is part of the ongoing Facial Recognition Vendor Test (FRVT) managed by NIST. The exercise simulated departing flights, populating galleries with photos of 420 arriving travelers at the airport, then measuring accuracy by running searches of photos at departure. IDEMIA’s technology conducted 536 simulated aircraft boardings, without experiencing a single false negative, which translates to a secure and frictionless boarding experience for passengers.

New Enhancements to OPEX® Sure Sort® Robotic Sorting System Expand Capabilities and Increase Productivity for Warehouse Automation Customers3.8.2021 16:10:00 EEST | Press release

OPEX® Corporation, a leading provider of innovative warehouse automation solutions worldwide, has made enhancements to one of its most popular products to better meet warehouse customers’ needs. First introduced in 2017, the Sure Sort® small-item robotic sorting system has revolutionized order fulfillment in e-commerce distribution centers worldwide due to its compact array of sort locations that can be scaled, sized, and customized in the small footprint of a single-pass put wall. Sure Sort quickly and accurately processes up to 2,400 items per hour with limited labor. Sure Sort easily directs a wide range of items, including cylindrical, clear, plastic bagged and blister pack items less than five pounds each. It can handle items as small as two inches in length and width and can support products as large as 15 inches long, 12 inches wide, and 6 inches high thanks to the new modifications OPEX just made. “Sure Sort previously only handled items four inches high,” said Monty McVaugh, M

New Members Have Joined HD-PLC Alliance to Accelerate the HD-PLC Advancement Towards a Global Power Line Communication Standard3.8.2021 16:00:00 EEST | Press release

HD-PLC Alliance (*1), Fukuoka, Japan (Alliance) announced that 4 newcomers has joined the alliance this year. The member list on Alliance website was updated as follows; MicroChip Technology as Supporter since July, is a leading provider of smart, connected and secure embedded control solutions. Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs which reduce risk while lowering total system cost and time to market. The company’s solutions serve more than 120,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. Microchip is headquartered in Chandler, Arizona. LVX Global, as Supporter since May, is an international technology solutions business that identifies, designs, delivers and manages high value, scalable, replicable social outcomes at the intersection of technology, engineering, and human behavioural science. Helvetia, as Standard since May, is a Japanes

SoftServe Opens New Office in Dubai3.8.2021 14:05:00 EEST | Press release

SoftServe, a leading global digital authority and consulting company, has opened a new office in Dubai as part of its initiative to support the rapidly expanding user base in the Middle East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210803005011/en/ (Graphic: Business Wire) SoftServe has been supporting customers in the region since 2018, delivering solutions for large conglomerate customers in the retail, finance, and energy sectors. As a developing and dynamic hub for investment with a growing population and considerable opportunity for activity in the non-oil sectors, the Middle East plays a crucial role in SoftServe’s growth strategy. The new office is located at Building No. 16, Dubai Internet City, Dubai, United Arab Emirates. “We are excited to bring our expertise to meet the growing demand for software development and digital transformation in this region,” says Volodymyr Semenyshyn, Executive Vice President EM

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom